Related Experiment Videos
Transcutaneous oxygen monitoring in aminophylline-treated apneic infants
Insights
Theophylline effectively reduced apnea and stabilized oxygen levels in premature infants. Longer treatment courses showed a lower rate of symptom recurrence compared to short-term therapy.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Respiratory Physiology
Background:
- Apnea of prematurity is a common challenge in neonatal care.
- Transcutaneous PO2 (tcPO2) monitoring provides continuous insight into gas exchange.
- Theophylline is a methylxanthine drug used to treat apnea in premature infants.
Purpose of the Study:
- To evaluate the efficacy of theophylline in managing apnea in premature infants.
- To assess the impact of theophylline on cardiorespiratory patterns and oxygenation using tcPO2 monitoring.
- To compare outcomes between short-term and long-term theophylline therapy.
Main Methods:
- Ten premature infants with apnea were enrolled.
- Theophylline was administered rectally in varying doses and durations (short and long courses).
- Continuous monitoring of tcPO2, heart rate, and thoracic impedance was performed, alongside polygraphic recordings and plasma level measurements.
Main Results:
- Theophylline administration altered cardiorespiratory patterns, regularized respirations, and reduced apneic spells.
- Oxygenation was stabilized, with decreased episodes of both hypoxia (low tcPO2) and hyperoxia (high tcPO2).
- Bradycardic episodes decreased, and longer treatment courses were associated with a lower frequency of symptom recurrence.
Conclusions:
- Theophylline is an effective treatment for apnea of prematurity, improving respiratory regularity and oxygenation.
- Continuous tcPO2 monitoring is a valuable tool for assessing drug effects on premature infants.
- Longer-term theophylline therapy may offer more sustained benefits in preventing the return of apneic symptoms.
Abstract:
Transcutaneous PO2 (tcPO2) monitoring offers a new approach to the evaluation of drug effects. We investigated the effect of theophylline on ten premature infants with apnea. Theophylline was administered as aminophylline, 8 mg/kg per rectum every 12 hours for two doses and 4 mg/kg every 12 hours for a total of two or five days (short and long courses). The tcPO2, heart rate (beat-to-beat), and thoracic impedance were continuously monitored during each of three 4-hour study periods: 12 hours before theophylline administration, 12 hours after initiation of theophylline therapy, and 24 to 48 hours after discontinuing the drug's use. Plasma levels were measured by a radioimmunoassay developed in our laboratory. Polygraphic recordings were analyzed without knowledge of treatment for frequency of apneic spells, mean duration of apneas, total duration of hypoxemia (tcPO2 less than or equal to 40 torr), total duration of hyperoxemia (tcPO2 greater than or equal to 100 torr), basal tcPO2, heart rate, and respiratory rate. In each case during theophylline use, cardiorespiratory patterns were altered, respirations were more regular, apneic spells were reduced, PO2 was stabilized with less hypoxia and hyperoxia, and bradycardic episodes were decreased. There was considerable variation in the response of the ten infants and a significant difference in the frequency of return of symptoms between those receiving short-term therapy and those receiving the longer course.